ACLARA and Cell Signaling Technology, Inc. Enter into Antibody Supply Agreement
December 04 2003 - 8:30AM
PR Newswire (US)
ACLARA and Cell Signaling Technology, Inc. Enter into Antibody
Supply Agreement MOUNTAIN VIEW, Calif. and BEVERLY, Mass., Dec. 4
/PRNewswire-FirstCall/ -- ACLARA BioSciences, Inc. and Cell
Signaling Technology, Inc. (CST), today announced the signing of a
supply and license agreement, for the use and resale by ACLARA of
certain CST reagents in conjunction with ACLARA's eTag(TM) Assay
System. These reagents include phospho-specific antibodies to key
signaling molecules such as kinases and related materials. CST has
expertise in the generation and commercialization of these types of
reagents, and has built a strong reputation for quality products.
Signal transduction pathways, and the molecules that comprise them,
chiefly kinases, have been an important focus for cell biology
research for many years. The significant role they play in
directing such critical processes as cell differentiation,
proliferation and death is now moving them to the forefront of
pharmaceutical discovery. For instance, the U.S. Food and Drug
Administration has approved two kinase inhibitors for use in
certain types of cancer: Gleevec(TM) from Novartis and Iressa(R)
from AstraZeneca. "We believe that, aided by highly specific
antibodies such as those from CST, ACLARA's multiplexed,
multi-label eTag Assay System will play an important role in the
characterization of signal transduction pathways in cells and
tissues, and the development of novel medicines targeting these
pathways," stated Michael Dunn, ACLARA's chief business officer.
The eTag system permits precise and reproducible quantification of
the activation state of kinases and other phosphoproteins in
complex biological samples, information that is very important to
researchers probing cellular pathways." "Cell Signaling Technology
is very excited about ACLARA's eTag technology as an important
discovery application for our antibodies," said Christopher Bunker,
CST's director of business development. "CST's antibodies provide
superior content that enable the unique types of cellular analysis
only possible with the eTag platform, and we anticipate that this
technology will be critical in advancing research toward targeted
therapeutics." About the eTag Assay System The eTag Assay System is
a high performance, high throughput system for the simultaneous
measurement of 10's to 100's of genes, proteins, and cell-based
antigens across thousands of samples. The eTag platform makes it
possible for researchers to measure multiple aspects of a complex
biological system, enabling the study of gene expression, protein
expression, cell signaling and pathway activation, protein-protein
interaction, post-translational modifications and cell receptor
binding -- all in the same sample and with the same platform. The
system uses ACLARA's proprietary eTag reporters to multiplex the
analysis of genes and/or proteins. Specific molecular binding
events result in the release of electrophoretically distinct eTag
reporters, which are then resolved by standard capillary
electrophoresis to provide precise, sensitive quantitation of
multiple analytes -- directly from cell lysates of cultured or
primary cells, as well as fresh and fixed tissue samples. ACLARA's
eTag Assay System is being commercialized for use both in drug
discovery research and to support preclinical and clinical
development of specific targeted therapies. These programs allow
scientists to utilize eTag reagent products, software, and
services. For multiplexed gene expression, ACLARA uses eTag
Multiplex Invader(R) Assays, which incorporate Invader technology
and Cleavase(R) enzyme and are licensed for use from Third Wave
Technologies, Inc. About ACLARA ACLARA BioSciences, Inc. is
developing advanced tools for drug discovery and development using
its proprietary eTag assay platform. The Company's products provide
researchers with decision-critical information for drug
development, which previously was difficult or impossible to
obtain. The solution-phase eTag Assay System is cost-effective,
easy-to-use and flexible, and enables highly accurate, precise and
sensitive analysis of genes and/or proteins from limited amounts of
biological samples. Importantly, researchers can use their existing
instrument platforms to perform eTag analyses. More information on
ACLARA can be obtained on the Company's web site at
http://www.aclara.com/. About Cell Signaling Technology Cell
Signaling Technology, Inc. has expertise and the market leadership
position in the development and commercialization of
phospho-specific antibodies for kinase and pathway activation
measurement. CST's phospho-specific antibodies are validated on an
array of cellular and biochemical assay platforms and are critical
reagents used in basic biomedical research, pharmaceutical drug
discovery, and clinical pathology. More information on CST can be
obtained at the Company's web site at http://www.cellsignal.com/
Forward Looking Statement All statements in this news release that
are not historical are forward-looking statements within the
meaning of the Securities Exchange Act of 1934 as amended. Such
forward-looking statements are subject to factors that could cause
actual results to differ materially for ACLARA from those
projected. Those factors include risks and uncertainties relating
to the performance of the Company's products, product development,
development and commercialization efforts, successful establishment
of and performance under collaborative and commercial agreements,
adoption of its technologies by pharmaceutical and biotechnology
companies, the validity and enforceability of patents, the possible
infringement of the intellectual property of others, technological
approaches of ACLARA and its competitors, and other risk factors
identified in the Company's Form 10-K for the year ended December
31, 2002 and Form 10-Q for the quarter ended September 30, 2003 as
filed with the Securities and Exchange Commission. Trademarks
ACLARA BioSciences, eTag, and the ACLARA logo are trademarks of
ACLARA BioSciences, Inc. Invader and Cleavase are registered
trademarks of Third Wave Technologies, Inc. Gleevec and Iressa are
trademarks of Novartis and AstraZeneca, respectively. DATASOURCE:
ACLARA BioSciences, Inc. CONTACT: Alfred Merriweather, VP, Finance
and CFO of ACLARA BioSciences, Inc., +1-650-210-1200, or Web site:
http://www.cellsignal.com/ Web site: http://www.aclara.com/
Copyright
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Oct 2023 to Oct 2024